Vycor Medical's NovaVision Unveils Its European Internet-Delivered Therapy Suite at the 30th Annual GNP Conference

BOCA RATON, Florida and MAGDEBURG, Germany, September 30, 2015 /PRNewswire/ --

NovaVision, a wholly owned subsidiary of Vycor Medical, Inc. ("Vycor") (OTCQB: VYCO), announced that it had showcased the European version of its Internet-delivered NovaVision Therapy Suite at the 30^th Annual GNP Conference in Lübeck, Germany last week.

NovaVision's therapy suite consists of Vision Restoration Therapy (VRT) and NeuroEyeCoach, an eye-movement compensation therapy. The therapy suite, which is delivered directly to patients' computers via the Internet, is designed to provide broad benefits to those who suffer from vision disorders due to stroke or brain injury. NovaVision plans to launch the therapy suite across Europe in the fourth quarter of 2015, initially in German and English.

The GNP, or Society for Neuropsychology, is the leading society for German-speaking neuropsychologists in Germany, Austria and Switzerland, with over 1,500 members, dedicated to the development and improvement of diagnostic and therapeutic techniques including patients with neurological brain damage. GNP members play an influential and important role in the rehabilitation and referral of potential NovaVision patients in rehabilitation centers, clinics and physician practices, as well as playing an important role in clinical research.

GNP conference attendees who tried the German language version of the therapy suite were impressed by the ease of use, affordability for patients and the two therapies' complementary, broad benefits.

Adrian Liddell, chairman of Vycor and managing director of NovaVision in Germany, commented: "We are encouraged by the positive reception of our NovaVision therapy suite launched in June in the U.S. We believe the anticipated launch of our Internet-delivered versions in Europe will enable us to offer a comprehensive and affordable therapy solution to patients and physicians out of our offices in Magdeburg, Germany and Aberdeen, UK. Our scalable vision therapy suite targets a multi-billion dollar market opportunity in Europe, where it can help the large number people who suffer vision related disorders following a stroke or brain injury."

In Europe, there are over 1.1 million new strokes per year and about 1 million hospitalized brain injury cases per year, and up to 30% of these may suffer a vision disorder. Two things happen when someone suffers from vision related disorders following a stroke or brain injury: there is a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT addresses the restoration of lost vision while NeuroEyeCoach addresses patients' difficulty with their eye movements and their ability to integrate visual information, allowing them to make the most of their remaining vision. The two therapies provided in a suite are therefore highly complementary. NovaVision will also provide German and English language Professional models, enabling physicians to register and monitor patients and also for clinics and centers to treat patients in-clinic under their supervision.

About Vycor Medical, Inc. 

Vycor Medical (OTCQB: VYCO) is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions. The company has a portfolio of FDA cleared medical solutions that are changing and improving lives every day. The company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach.

Vycor Medical's ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU - Class III), Korea and Japan and is seeking or has partial regulatory approvals in India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical's VBAS, see VBAS Video.

NovaVision provides non-invasive, computer-based rehabilitation targeted at a substantial and largely un-addressed market of people who have lost their sight as a result of stroke, or brain injury. NovaVision's family of therapies both restore and compensate for lost vision. NovaVision's VRT is the only medical device aimed at the restoration of vision lost as a result of neurological damage which has FDA 510(k) clearance to be marketed in the U.S. NeuroEyeCoach is a compensation therapy registered in the US as a Class I 510(k) exempt device, VRT and NeuroEyeCoach are highly complementary and provided to patients in an Internet-delivered suite, to ensure broad benefits to patients. For an overview of NovaVision see NovaVision Video.

For the latest information on the company, including media and other coverage, and to learn more, visit http://www.vycormedical.com, http://www.vycorvbas.com or http://www.novavision.com.    

Investor Relations:
Liolios Group, Inc.
Ronald A. Both
Tel 1-949-574-3860
[email protected]

SOURCE Vycor Medical, Inc.